Mechanistic target of rapamycin (mTOR) serves as a sensor of metabolic cues and as a regulator of growth, proliferation, and survival in eukaryotic cells. mTOR was initially identified as the molecular target of an anti fungal macrolide antibiotic produced by the bacterium Streptomyces hygroscopicus. This bacterium was discov ered in a soil sample from Easter Island, known to its inhabitants as Rapa Nui, from which the name rapa mycin was derived 1 . Rapamycin is a potent inhibitor of antigeninduced proliferation of T cells 2 and, owing to this activity, has been developed as a medication to prevent organ transplant rejection 3 . Rapamycin was approved by the FDA to preserve renal allografts under the generic name sirolimus 4 . The potency of sirolimus in blocking Tcell activation was first found to be beneficial in the treatment of rheu matic diseases in the context of systemic lupus erythe matosus (SLE), both in animal models 5 and in patients 6 .
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. Rapamycin is a potent inhibitor of antigeninduced proliferation of T cells 2 and, owing to this activity, has been developed as a medication to prevent organ transplant rejection 3 . Rapamycin was approved by the FDA to preserve renal allografts under the generic name sirolimus 4 . The potency of sirolimus in blocking Tcell activation was first found to be beneficial in the treatment of rheu matic diseases in the context of systemic lupus erythe matosus (SLE), both in animal models 5 and in patients 6 .
Rapamycin and its analogues (rapalogues) were also effi cacious in animal models 7 and patients with rheumatoid arthritis (RA) 8 , juvenile idiopathic arthritis (JIA) 9 and Sjögren syndrome 10 . In patients with systemic sclerosis (SSc), mTOR activation contributes to type I collagen pro duction by dermal fibroblasts 11, 12 , and rapamycin improves skin fibrosis 13 and reduces osteopenia in a mouse model of the disease 14 . A pilot study of rapamycin in patients with SSc showed limited efficacy, but the treatment was determined safe 15 . Rapamycineluting endovascular stents have also been used to treat largevessel vasculitis, aortitis 16 and Takayasu arteritis 17 , but the drug has lim ited clinical efficacy in patients with granulomatosis with poly angiitis (GPA) 18 , despite lowering titers of myeloper oxidase and perinuclear antineutrophil cytoplasmic anti bodies (pANCA) 19 . By stimulating autophagy, rapamycin improves the survival of human articular chondrocytes and, thereby, benefits patients with osteoarthritis (OA) 20 . A long list of studies supports a role for the mTOR pathway in the pathogenesis of both inflammatory and degenerative rheumatic diseases. In this Review, I criti cally evaluate the mechanisms of mTOR activation and the means for its pharmacological blockade, which have broad implications for the pathogenesis, diagnosis and management of rheumatic diseases.
Biology of mTOR complexes
As a serine/threonine kinase, mTOR phosphorylates four signature substrates: S6K (ribosomal S6 kinase), which controls protein translation via ribosome bio genesis 21 ; 4EBP1 (eukaryotic translation initiation factor 4Ebinding protein 1), which regulates mRNA translation 22 ; signal transducer and activator of tran scription (STAT)3 (on Ser727) in response to amino acid excess 23 ; and AMBRA1 (activating molecule in BECN1 (beclin1)regulated autophagy protein 1), which pre vents serine/threonineprotein kinase ULK1/ATG1 from binding to membranes and starting autophagosome for mation 24, 25 (FIG. 1) . mTORdependent growth signals are triggered by metabolic cues (FIG. 1) such as amino acid sufficiency 26, 27 and oxidative 28, 29 or nitrosative stress 30 . In turn, activation of mTOR executes celltypespecific commands for growth, proliferation and survival via two interactive complexes -mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (FIG. 1) .
Intracellular localization and trafficking
The presence of mTOR in several cellular compartments could be key to its ability to sense stress and execute cellgrowth signals. mTORC1 was initially detected in the cytoplasm as a stimulator of protein transla tion by its ability to phosphorylate S6K 21 and 4EBP1 (REF. 31 ). Later, observations showing that mTOR was associated with endosomal compartments brought the traffickingregulatory small Rab GTPases Rab7 and Rab4A, as well as the Rag family of Rasrelated GTP binding proteins, to the forefront of the cellsignalling field 30, 32 . mTOR was also reported to translocate to the outer mitochondrial membrane, where it senses changes in the mitochondrial transmembrane poten tial, ATP depletion and oxidative stress 33 . Additionally, mTOR can also be detected inside the nucleus, where it might have a role in the transcription of RNA poly merase Idependent and RNA polymerase IIIdependent genes 34, 35 . Under conditions of cell stress, mTORC1 is sequestered in an astrin (also known as spermassociated antigen 5)dependent manner within stress granules, limiting cell growth and promoting cell survival 29 .
Consensus is increasing that mTORC1 activation occurs at the surface of the lysosomal membrane in response to changes in amino acid sufficiency 27 , which is transduced via the Rag family of small GTPases to medi ate the translocation of mTORC1 from the cytoplasm to the surface of the lysosome, where mTORC1 is activated by GTPbinding protein Rheb (FIG. 2) .
The translocation of mTOR to the lysosomal mem brane occurs via endosome traffic that is regulated by Rab7 (REF. 32 ), Rab5 and Rab4A. Each of these GTPases also regulates autophagy 37, [39] [40] [41] [42] (FIG. 2) .
Rab4A forms a positive feedback loop with mTORC1 and negative feedback loop with mTORC2 (REF. 43 ), and binds to the p85 regulatory subunit of phosphatidylinositide 3kinase (PI3K), altering its ability to control endocytic recycling [44] [45] [46] [47] . Notably, Rab4A and Rab5 are overexpressed in T cells of patients with SLE 30 and in mouse models of this disease 41 ; thus, these small GTPases are possible reg ulators of abnormal Tcell signal transduction in SLE. Furthermore, overexpression of Rab4A, but not Rab5, also precedes the production of antinuclear antibodies (ANA) and SLE onset 41 . Importantly, pharmacological inhibition of Rab GTPases by 3(3pyridyl)2hydroxy 2phosphono propanoic acid (3PEHPC) prevents Tcell dysfunction, ANA production, and nephritis in lupusprone mice 41 (FIG. 2) .
The celltypespecific activation of mTORC1, and its localization to the lysosome during autophagy, are subject to intricate control by metabolic regulatory net works 48 . Moreover, the traffic of endosomes to lysosomes has long been implicated in interferon production and inflammation, because these structures also carry Toll like receptors, which are able to sense nucleic acids, particularly in dendritic cells (DCs) 49 .
Metabolic regulatory networks
Signalling pathways that control the proliferation, sur vival and differentiation of cells in the immune system also regulate the metabolic processes that provide the nutrients required to support these specialized lympho cyte functions 50 . Although mTOR drives proinflamma tory lineage specification in the Tcell compartment 51 , it might also have antiinflammatory effects driven by shifting macrophage polarization from a proinflamma tory M1 phenotype to an antiinflammatory M2 pheno type (REFS 52, 53) . Nevertheless, M2 macrophages can also contribute to inflammation, for example by serv ing as hosts to cytomegalovirus (CMV), which might explain the potent antiCMV effects of mTOR inhibitors after organ transplantation 54 .
Outside the immune system, mTOR activation contributes to type I collagen production by dermal fibroblasts and to fibrosis in patients with SSc 11, 12 . In chondrocytes, genetic inactivation of mTOR pre vented the development of OA induced by peroxisome proliferatoractivated receptorγ (PPARγ) deficiency 55 . Furthermore, mTOR blockade with Nacetylcysteine
Key points
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Amino acids. The branched chain amino acids leucine and isoleucine are stimulators of mTOR 57 , and glutamine, a particularly important amino acid in cellgrowth con trol, can activate mTORC1 (REF. 58) . Unlike leucine, which relies on RagA and RagB, glutamine utilizes a different GTPase, ADPribosylation factor 1, to activate mTORC1 on the lysosome 59 (FIG. 1) . A comprehensive metabolome Nature Reviews | Rheumatology Figure 1 | mTOR pathway activation. Mechanistic target of rapamycin (mTOR) is regulated by metabolic cues, primarily glucose and amino acids, as well as by growth factors, hormones and cytokines. Glucose and amino acids enter cells via surface receptors such as glucose transporter type 1, erythrocyte/brain (GLUT1) or glucose transporter type 4, insulin-responsive (GLUT4) and CD98, respectively. Growth factors stimulate tyrosine kinase receptors (TKRs), which are activated through phosphorylation of tyrosine residues. In turn, TKR signals are transmitted to mTOR through phosphatidylinositide 3-kinase (PI3K), phosphoinositide-dependent kinase-1 (PDK1) and RAC serine/threonine-protein kinase (AKT). Signalling through sphingosine 1-phosphate receptor 1 (S1P 1 ) also activates mTOR complex 1 (mTORC1) via PI3K. Downstream, AKT phosphorylates mTOR, which forms two interacting complexes, mTORC1 and mTORC2. mTORC1 is composed of mTOR, regulatory-associated protein of TOR (raptor), TORC subunit LST8 (LST8), DEP-domain-containing mTOR-interacting protein (deptor) and proline-rich AKT1 substrate 1 (AKT1S1) 230 . mTORC2 is comprised of mTOR, rapamycin-insensitive companion of mTOR (rictor), stress-activated protein kinase interacting protein 1 (mSIN1, also known as TORC2 subunit MAPKAP1), protein observed with rictor-1 (protor-1), deptor and LST8. mTORC1 integrates growth signals reflecting the availability of nutrients and energy to promote either proliferation when conditions are favourable or autophagy when conditions are unfavorable; mTORC2 promotes cellular survival by activating AKT 82 . Pharmacologically targetable checkpoints are highlighted in yellow. 4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1; AMBRA1, activating molecule in BECN1-regulated autophagy protein 1; AMPK, 5'-AMP-activated protein kinase; Arf1, ADP-ribosylation factor 1; FKBP12, peptidyl-prolyl cis-trans isomerase FKBP12; HIF1α, hypoxia-inducible factor 1α; NAC, N-acetylcysteine; PKCα, protein kinase C α type; PTEN, phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; RAPA, rapamycin; Rag-A/B, Ras-related GTP-binding protein A/B; ROI, reactive oxygen intermediate; S6K, ribosomal protein S6 kinase; SREBP1, sterol regulatory element-binding protein 1; STAT3, signal transducer and activator of transcription 3.
analysis identified a redoxdependent accumulation of kynurenine, an aminoacid metabolite of tryptophan, in lymphocytes from patients with SLE 60 ; kynurenine also triggers mTORC1 activation in T cells 60 .
Pentose-phosphate pathway. Upon activation, mTORC1 promotes the transcription of genes involved in glyc olysis, in the pentosephosphate pathway (PPP) and in de novo lipogenesis 61 . Upregulation of glycolysis is mediated via the transcription factor hypoxiainducible factor 1α (HIF1α) 62, 63 (FIG. 1) . As shown in a 2013 metabo lomic study, most of the mTORC1regulated metabolites are part of the PPP 64 . Notably, mTORC1dependent acti vation of the PPP was found to be dependent on oestro gen 65 , which promotes surface expression of GLUT1 (glucose transporter type 1, also known as solute car rier family 2, facilitated glucose transporter member 1) and GLUT4 (solute carrier family 2, facilitated glucose transporter member 4) -two proteins that are required for glucose uptake to fuel the PPP 65 . This finding could be associated with the increased prevalence of SLE in women, who display increases in both expression and activity of the PPP enzyme transaldolase, and increased activation of mTORC1 (REF. 30 ).
cAMP. The second messenger cAMP regulates a diverse array of biological processes, mostly via its downstream effector, protein kinase A (PKA) 66 . Ample evidence supports the existence of crosstalk between the PKA and mTOR pathways: for example, cAMP can stim ulate mTORC1 (REFS 67, 68) or inhibit both mTORC1 and mTORC2 in a celltypedependent manner 60, 69 . Importantly, blockade of mTORC1 activation in T cells reduces cAMP levels in peripheral blood lymphocytes (PBL) from patients with SLE after treatment with NAC in vivo 70 . Nature Reviews | Rheumatology Fatty acid synthesis. De novo fattyacid synthesis is essential for the proliferation and differentiation of T helper (T H ) type 17 cells, whereas fattyacid catabo lism via βoxidation is important for the development of CD8 + memory T cells 71 and CD4 + T regulatory (T REG ) cells 72 . In addition to serving as a source of energy, lipids contribute to cellular structures and signalling. Sphingolipids, particularly sphingosine1phosphate (S1P), are emerging as vital lipid mediators 73 (FIG. 1) . S1P signals through five known Gprotein-coupled receptors, S1P receptors 1-5 (S1P 1 to S1P 5 ) 74 . S1P 1 , the main S1P receptor that facilitates the egress of T cells from lymphoid organs 75 , exerts a negative control of the thymic generation and suppressive activity of nat ural T REG cells, a process which is dependent on the Akt-mTOR axis 76 . Transgenic overexpression of S1P 1 Oxidative stress. Oxidative stress activates the mTOR pathway in most cells [28] [29] [30] 33 by a process that involves cysteine oxidation of Rheb 78 and raptor (regulatoryassociated protein of mTOR) 28, 79 . With esca lation of oxidative stress, astrin recruits the mTORC1 component raptor to stress granules, thereby preventing mTORC1hyperactivation in HeLa cells 78 . Whether astrin is expressed and capable of similarly controlling mTORC1 activation in primary cells is currently unknown, but such a mechanism could be important in the survival of CD4 − CD8
− (doublenegative, DN) T cells in SLE, and possi bly in other proinflammatory cells, such as fibroblasts or osteo clasts, which are exposed to oxidative stress in patients with rheumatic diseases.
Stimulatory and inhibitory signal transducers
The mTOR pathway is largely controlled by upstream checkpoints at three levels: receptor tyrosine kinases and Gproteincoupled receptors, which detect growth factors; the PI3K-PDK1 (phosphoinositidedependent kinase1)-AKT (RACα serine/threonineprotein kinase) axis, which channels stimulatory signals towards mTORC1 activation; and the key negative regulators PTEN, AMPK (5ʹAMPactivated protein kinase cata lytic subunit α2), TSC1 and TSC2 (the latter two are also known as hamartin and tuberin, respectively).
The PI3K-AKT-mTOR axis. At the level of the organ ism, the PI3K-AKT-mTOR signalling network enables the development of celltypespecific responses that integrate changes in intracellular metabolism and expo sure to a variety of growth factors, as well as transmitting signals from intercellular receptor-ligand interactions.
The upstream enzyme of this signalling network is class I PI3K. PI3K is activated by receptor tyro sine kinases and autophosphorylation in response to extra cellular signals such as ligand binding (FIG. 1) . Upon activation, PI3K generates phosphatidylinositol3,4,5 trisphosphate (PIP 3 ) 80 , which recruits pleckstrin homol ogy domaincontaining signalling proteins such as AKT to the plasma membrane 81 . PDK1, which also contains a pleckstrin homology domain and can bind PIP 3 , is then recruited to the plasma membrane upon activa tion of PI3K and leads to the phosphorylation of AKT and its partial activation. Full activation of AKT occurs upon phosphorylation of Ser473 by mTORC2 and other kinases 82 (FIG. 1) .
Class II PI3K interacts with Rab5 and thereby con trols endosomal activation of AKT 83 . The class III PI3K vacuolar protein sortingassociated protein 34 (VPS34, also known as PI3K catalytic subunit type 3), is tethered to endosomal membranes and directs the trafficking of proteins and vesicles, thus contributing to phagocytosis and autophagy 81 . The activity of VPS34 during auto phagy is regulated by AMPK in response to nutrient stress responses 84 .
PTEN. PTEN dephosphorylates membrane phosphati dylinositols and, thereby, can operate as an inhibitor of the AKT-mTORC1 axis (FIG. 1) . PTEN directly antago nizes PI3K by dephosphorylating PIP 3 and has impor tant roles in chromosome stability, DNA repair, and cellcycle arrest in the nucleus 85 . Mutations of PTEN cause Cowden syndrome, which has been associated with inflammatory arthritis 86 and SLE
87
. The role of PTEN in pathogenesis of rheumatic dis eases is also supported by mechanistic studies. PTEN is essential for the maintenance of functional capacity of T REG cells, which restrain the expansion of proinflam matory T H 1, T H 17, and T follicular helper (T FH ) cells in autoimmune diseases [88] [89] [90] . In B cells from patients with SLE, increased levels of microRNA (miR)7, miR21 and miR22 inhibit PTEN expression 91 . Loss of PTEN also increases the osteoclastogenic potential of mye loid cells, leading to enhanced local inflammation and bone destruction 92 .
LKB1-AMPK axis.
The axis formed by liver kinase B1 (LKB1) and 5´AMPactivated protein kinase (AMPK) is an important regulator of the mTORC1dependent translation process. AMPK activation by LKB1 inhib its the mTORC1 pathway via phosphorylation of TSC2 (REF. 93 ) and Raptor 94 . Under energy starvation condi tions, an increase in AMP levels stimulates the activity of AMPK 95 and inhibits mTORC1 signalling 93 (FIG. 1) . In activated T cells, AMPK serves as a glucosesensitive metabolic checkpoint that regulates mRNA translation and glutaminedependent mitochondrial metabolism: T cells lacking AMPKα1 display reduced mitochon drial bioenergetics and cellular ATP levels in response to glucose deprivation in vitro or pathogenic challenge in vivo 93 . AMPKα1 is also essential for T H 1 and T H 17 cell development and for primary Tcell responses to viral and bacterial infections in vivo; AMPKα1deficient macrophages and DCs exhibit heightened inflammatory function, an enhanced capacity for antigen presentation and favour T H 1 and T H 17 responses 96 . Further studies are necessary to examine whether the effects of AMPK on Tcell and Bcell development are independent from its inhibitory effect on the mTORC1 pathway.
AMPK also has a key role in activating pro autophagic VPS34 complexes 84 by phosphorylating beclin1. This initial step of autophagy can be blocked by mTOR through phosphorylation of AMBRA1; con versely, mTORC1 inhibition leads to phosphoryl ation of beclin1 and propagates autophagosome forma tion 97 . PBLs from patients with SLE exhibit increased mTORC1 activity 30 and profoundly diminished beclin1 expression, a state that is reversed by rapa mycin treatment in vivo 41 . Remarkably, mechanical stress, which is the primary inducer of OA, reduces beclin1 expression and autophagy in chondro cytes, and treatment with rapamycin reverses these changes 98 . Thus, mTORC1dependent beclin1 expres sion is a celltypespecific regulator of autophagy in rheumatic diseases.
Cell-type-specific activation of mTOR
The mTOR pathway has critical roles in the develop ment and function of the innate and adaptive arms of the immune system. An essential role of mTOR in Tcell development was uncovered 51 when mTORC1 was found to be required for the differentiation of T H 1 and T H 17 cells, whereas T H 2cell development depends on mTORC2 (REF. 51 ). mTORC1 also inhibits the survival of CD8 + memory T cells, an effect that can be reversed by rapamycin treatment 99, 100 . Both mTORC1 and mTORC2 seem to interfere with the differentiation and function of CD4 + CD25 + FoxP3 + T REG cells 51, 77, 101 , but mTORC1 might also support T REG cell function 102 by inhibiting the mTORC2 pathway 103 .
Despite its complex role in T REG cell function, the largely proinflammatory changes elicited by mTORC1 activation in the adaptive immune system are in appar ent contrast with its antiinflammatory effects on the innate immune system (for example, mTORC1 favours M2 over M1 polarization of macrophages 52 ). The cell typespecific activation of mTORC1 also varies between rheumatic diseases, as mTORC1 is activated in T cells of patients with SLE 30 , but not in those of patients with RA 104 . These divergent effects of mTOR activation in T cells might be connected to alternative use of glucose between glycolysis and the PPP 105 . mTOR -biomarker and pathogenetic factor mTORC1 activation in SLE In patients with SLE, mTORC1 is activated 30, 70 and mTORC2 is inhibited 106 (FIG. 2) . A central role for mTORC1 in abnormal Tcell lineage specification and function in SLE 30, 107, 108 is consistent with its effects on shaping Tcell development 51 . The involvement of mTOR in SLE was initially sug gested by the successful blockade of Tcell hyperactiv ity and nephritis in rapamycintreated lupusprone MRL/lpr mice 5 . Later, rapamycin was shown to block Tcell activation in patients with SLE 30 , with remark able therapeutic efficacy 6, 109 . Interestingly, activation of mTORC1 preceded disease flares by 4 months, and was reduced by therapeutic intervention with rapa mycin 109 . Thus, measurement of mTORC1 and mTORC2 activity by intracellular staining for phosphorylated 40S ribo somal protein S6 (at Ser235 and Ser236) and phospho rylated AKT (at Ser473), respectively, can be used as biomarkers for pathogenesis, prediction of flares and monitoring of treatment efficacy of mTOR blockade in SLE 70, 106, 109 . Measuring the activity of mTORC1 and mTORC2 in cells of patients with SLE and other auto immune diseases could be another step in achieving personalized or precision medicine 110 . Rapamycin blocks the proinflammatory, necrotic death of DN T cells and the depletion of T REG cells 109 , and mTORC1 inhibition by NAC had similar effects 111 (FIGS 1,2; TABLE 1). Diminished T REG cell frequency has been linked to mTORC1sensitive methylation of the Foxp3 promoter 112 , whereas rapamycin treatment reduced the production of IL4 by DN T cells in vivo 109 , account ing for an increased production of antiDNA autoanti bodies by B cells 113, 114 . The benefits of rapamycin can also be attributed to T REG cell expansion 109 via activation of mTORC2, at least in patients with SLE 106 . Given the role of mTORC2 signalling in T REG cells and in regulating the development of T FH cells 89, 90, 115 , which are expanded in mouse models of lupus 116 and in patients with active SLE 117 , the impact of rapamycin on the proinflammatory DN Tcell subset merits further investigation. The docu mentation of the first clinical case of fulminant SLE in a patient with tuberous sclerosis also support a fundamen tal role of mTOR pathway activation in the pathogenesis of both these diseases 118 : in accordance with a negative regulatory role for the TSC1-TSC2 complex, all lympho cyte subsets of this patient exhibited robust mTORC1 activation 118 . mTORC1 is also activated in B cells 119 and nephritic kidneys of lupusprone mice 120 (FIG. 3) .
Antiphospholipid antibodies (aPL) trigger consid erable pathology and are one of the diagnostic criteria for SLE [121] [122] [123] . Moreover, aPL can elicit antiphospholipid syndrome (APS) in patients with or without SLE 124 . As shown in a 2014 study, seven of ten patients with APS nephropathy treated with rapamycin (70%) had a functioning allograft 144 months after transplantation, versus only three of 27 patients who were not treated with rapamycin (11%) 125 . Notably, the majority of the patients with APS had also been diagnosed with SLE (20 of 32 patients, 62%) 125 . Unfortunately, the researchers did not document how many of the seven patients who benefited from rapamcyin 125 also had SLE. mTORC1 activity is not elevated in major PBL subsets of patients with SLE who also have APS, relative to those without APS 126 . Therefore, rapamycin might have benefited renal transplant recipients with underlying SLE 125 . The mTORC1 inhibitor NAC reversed the depletion of reduced glutathione (GSH) in PBLs of patients with SLE in a doubleblind, placebocontrolled, phase I-II clinical trial 70 . Of relevance to its mechanism of action, NAC also reversed the strong activation of mTORC1 in DN T cells, which is consistent with a role of oxidative stress as a regulatory checkpoint. Oxidative stress origi nates from increased mitochondrial oxygen consumption by complex I of the electron transport chain in T cells from patients with SLE 127 . Along this line, inhibition of mitochondrial oxidative stress with metformin also reduced mTORC1 activity and prevented nephritis in lupusprone mice 128 . Therefore, these findings support a role for oxidative stress in both activation of mTORC1 and the pathogenesis of lupus nephritis in mice 28, 29 .
In addition to oxidative stress, traffic to the lysoso mal membrane and the detection of aminoacid suffi ciency have been implicated in the activation of mTORC1 (REF. 27) . A 2015 metabolome analysis unveiled a NAC responsive accumulation of kynurenine in SLE PBLs 60 as the strongest metabolic predictor of SLE when comparing patients with matched healthy individuals 60 . Kynurenine was also the strongest predictor of the NAC effect on the mTOR pathway in patients with SLE. In addition to lowering kynurenine levels, NAC greatly augmented the levels of NADPH, an effect thought to occur via sparing of NADPH through enhancement of de novo GSH syn thesis 129, 130 (FIG. 2) . Importantly, kynurenine also triggered mTORC1 activation, particularly in DN T lymphocytes 60 . Therefore, NACresponsive accumulation of kynure nine is a biomarker of oxidative stress and a trigger of mTORC1 activation -two mechanistically connected metabolic checkpoints in SLE pathogenesis 60 . This com prehensive metabolomic study also revealed a depletion of cysteine in SLE PBLs 60 , further supporting the use of NAC treatment in SLE.
Rheumatoid arthritis
The role of mTOR is far less thoroughly characterized in RA than it is in SLE 131 . Unlike CD4 T cells in SLE, CD4 T cells from patients with RA show no significant changes in mTOR activity 104, 132 . Of note, RA T cells exhibit diminished glycolytic activity, thus depriving them of the energy required to generate oxidative stress or to execute autophagy 104 . Despite the lack of changes in mTOR activ ity in RA T cells, rapamycin and rapalogues have shown efficacy in reducing joint inflammation in animal models of arthritis 7 and in patients with RA 8 or JIA 9 . Such clinical benefits might accrue from the inhibition of mTORC1 activation in fibroblastlike synoviocytes (FLS) 133 (FIG. 3) .
In support of this notion, rapamycin decreased the inva sive properties of RA FLS 133 . Additional evidence of the benefits of mTORC1 inhibition in RA includes the ability of IL17 to induce mTORC1dependent proliferation of RA FLS 134 , the increase in mTORC1 activity in osteoclasts from patients with RA and in arthritic transgenic mice 7 , and the downregulation of extracellular matrix digestive enzymes and induction of apoptosis in osteoclasts elic ited by mTOR inhibition 7 (FIG. 3) . Taken together, these observations suggest a therapeutic benefit from mTOR blockade in RA that might involve the intraarticular cells that mediate erosive joint destruction.
Ankylosing spondylitis
Ankylosing spondylitis (AS) is a chronic inflammatory disease that predominantly affects the axial skeleton, with variable involvement of the peripheral joints and nonarticular structures, such as the heart valves and the eyes 135 . HLAB27 has been recognized as the most important genetic risk factor for AS, but genome wide association studies (GWAS) have now identified two ASassociated chromosomal loci independent of HLAB27 that encode four endoplasmic reticulum aminopeptidases (ERAPs), which are involved in pep tide processing before MHC class I presentation [136] [137] [138] . Although MHC class I peptides are primarily presented to CD8 T cells, IL12
+ and IL23 + CD4 T cells (which can be converted to T H 17 cells), have been also implicated as responders to antigenpresenting macrophages and DCs in the inflamed spine of patients with AS 139 . The upregulation of let7i miRNA, which contrib utes to IFNγ production, might also account for Tcell hyperreactivity in patients with AS 140 , as insulinlike growth factor1 receptor (IGF1R) is a direct target of let7i in T cells from these patients 141 . IGF1R mediates its effect by activation of the PI3K-AKT-mTOR path way [140] [141] [142] [143] . Interestingly, let7i overexpression increases autophagy, but inhibits apoptosis; thus, let7i contributes to Tcell dysfunction in patients with AS 141 . Moreover, unbiased proteomics studies found evidence for activa tion of PI3K, fattyacid oxidation and insulin signalling in fibroblastlike ligament cells of patients with AS 144 . Given all these findings, mTORcontrolled metabolic pathways are likely to shape the repertoire of both adaptive and innate inflammatory cells in AS (FIG. 3) . CaMK-II/IV, calcium/calmodulin-dependent protein kinase type II/IV; CIA, collagen-induced arthritis; ETC, electron transport chain; GSH, reduced glutathione; ILD, interstitial lung disease; JIA, juvenile idiopathic arthritis; mTOR, mechanistic target of rapamycin; mTORC1/2, mechanistic target of rapamycin complex 1/2; NAC, N-acetylcysteine; SSc, systemic sclerosis; S1P, sphingosine-1-phosphate; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis.
Psoriatic arthritis
T H 17 cells have pivotal roles in orchestrating the inflamma tion in the skin and joints of patients with psoriatic arthri tis (PsA) 145 .
Regarding the prominent expansion of T H 17 cells, a paucity of studies have examined its association with mTOR activation in PsA or psoriasis. Importantly, GWAS in patients with psoriasis (20-30% of whom also have PsA) uncovered a link with a singlenucleotide polymorphism in Raptor, a component of mTORC1 (REF. 146) . Whereas the functional consequences of this genetic association have not been evaluated, the involve ment of mTORC1 in PsA is independently supported by mechanistic studies. As is also observed in patients with RA, the proliferation of FLSs (which can be triggered by IL22) is mediated by the PI3K-Akt-mTOR cascade in patients with PsA 147 (FIG. 3) . Unlike RA T cells, however, PsA T cells exhibit increased signalling through the AKTmTOR axis 148 ; this observation may result from increased expression of programmed death1 (PD1) in T cells from patients with PsA 148 . The mTOR pathway has also been implicated in keratinocyte hyperproliferation (FIG. 3) , as rapamycin was found to arrest human keratinocyte stem cells in the G1 phase 149 . Evidence of mTORC1 activation is also provided by the increased phosphorylation of mTOR and S6K in punch biopsy samples of psoriatic skin lesions 150, 151 .
Systemic sclerosis
Activation of the mTOR pathway has a central role in the proliferation of fibroblasts (FIG. 3) , the cells that mediate skin lesions in the limited cutaneous form of SSc and in other involved organs in progressive SSc. Signalling through the PI3K-AKT-mTOR axis can be initiated by transforming growth factor β (TGFβ) and its proximal effectors, Smad2 and Smad3 (REFS 152, 153) . Supporting a critical role for mTOR in these diseases, rapamycin abrogates TGFβinduced fibroblast growth 154 . As men tioned previously, mTORC1 activation also contributes to type I collagen production by fibroblasts, the pro cess that leads to fibrosis in SSc skin lesions 11, 12 and is inhibited by rapamycin 13 . In a pilot study of patients with progressive SSc, rapamycin was safe, although it had limited efficacy 15 . TGFβ also activates mTORC2 in skin fibroblasts, as evidenced by increased phosphoryl ation of AKT at Ser473 154 , and mTORC2 activity also contributes to kidney fibrosis 155 .
Osteoarthritis
The pathogenesis of OA originates from excessive mechanical stress and a systemic susceptibility 156 . The disease process is characterized by progressive cartilage loss, subchondral bone remodelling, osteophyte for mation and synovial inflammation. Notably, cartilage loss might be therapeutically targeted via mTOR block ade. Mechanical stress activates the mTOR pathway in chondrocytes during chondrogenesis and cartilage development 157 (FIG. 3) . In turn, treatment with rapamy cin blocks the mechanicalstressinduced proliferation of chondrocytes in vitro 157 . Thus, blockade of mTORC1 in chondrocytes might not itself be beneficial, but human articular chondrocytes also employ the mTOR pathway to control autophagy, which initiates the release of articular cartilage vesicles (ACVs) into the cartilage matrix 20 . Interestingly, rapamycin promotes autophagy and consequently increases the release of ACVs by nor mal chondrocytes, whereas OA chondrocytes fail to increase ACV release in response to mTOR inhibition. These findings indicate that the autophagy defects in OA are downstream of mTOR activation 20 . Nevertheless, intervening at a critical step in the regulation of auto phagy could potentially slow the adverse effects of age ing on cartilage homeostasis, which increase the risk of developing OA 158 . Indeed, cartilagespecific inactiva tion of mTOR enhances autophagy and protects against meniscusablationinduced OA; treated animals show a substantial reduction in articular cartilage degradation, apoptosis and synovial fibrosis 159 . This substantial effect of rapamycin treatment on OA prevention is remark able, given that it also extends lifespan in mice 160 . More over, the inhibition of OA by rapamycin might also improve the quality of life of patients with this disease.
mTOR as a therapeutic target in rheumatic disease As mentioned previously, sirolimus was initially approved by the FDA for preservation of renal allograft function owing to its capacity to inhibit Tcell proliferation 4 . As its molecular target, mTOR 161 , is involved in many cellular processes (including protein translation, growth, prolifer ation, survival and autophagy) that function abnormally in autoimmune, inflammatory and degenerative dis eases (as well as in cancer) in a celltypespecific man ner, >1,800 clinical trials have been registered 162 to test this drug in diverse disease conditions; this number does not include studies of sirolimus analogues (for example, everolimus), dual mTORC1 and mTORC1 inhibitors, PI3K or AKT inhibitors [163] [164] [165] [166] [167] .
Rapamycin, rapalogues and mTORC1/2 inhibitors
Rapamycin is an allosteric inhibitor of mTOR that acts by forming a highaffinity complex with the 12 kD intracel lular protein FKBP12 (peptidylprolyl cistrans isomerase FKBP1B) 168 (FIG. 1) . The resulting complex of rapamycin and FKBP12 blocks mTOR activation in yeast 169 and mammalian cells 161 . mTOR blockade by rapamycin seems to primarily affect mTORC1 (REFS 170, 171) , and might cause a secondary activation of mTORC2 (REF. 82 ).
The duration of treatment with rapamycin is critical for mTORC1 selectivity. Whereas 2 weeks of treatment in mice blocks only mTORC1, leading to detrimen tal metabolic effects, 6 weeks of treatment leads to a state of metabolic transition, and 20 weeks of treatment improves metabolic profiles and insulin sensitivity by also reducing activity of mTORC2 (REF. 172 ). In T cells from healthy individuals and patients with SLE, rapamy cin treatment in vitro reduced mTORC1 and enhanced mTORC2 activity 106 . Although the activity of mTORC2 is reduced in DN T cells from these patients, as evidenced by diminished phosphorylation of AKT at Ser473 106 , whether longterm treatment with rapamycin also acti vates mTORC2 in vivo is currently unknown. Therefore, whether the therapeutic benefit of rapamycin in patients with SLE originates solely from blockade of mTORC1, or whether it also involves activation of mTORC2, is also unclear. Given the role of mTORC2 in control of T REG cell survival and function [88] [89] [90] , studies should be pursued in patients with SLE and other autoimmune diseases to dissect the exact mechanism of action of rapamycin. In the event that mTORC2 is activated by rapamycin in vivo, ATPcompetitive, dual mTORC1 and mTORC2 inhibitors (such as torin 1 or sapanisertib) could be even more effec tive 173 . Importantly, the ATPcompetitive dual inhibitor torkinib reduces the expression of cholesterol biosynthesis genes in a 4EBP1dependent manner 174 . Dual inhibitors are currently in clinical trials in cancer patients.
Rapamycin has shown great potency in blocking the development of SLE in the MRL/lpr 5 and NZB/W F1 animal models 41, 175 , in which autoimmunity, Tcell hyperreactivity, titres of ANA and antiDNA antibod ies, glomerular immunoglobulin deposition, protein uria, nephritis, and overall survival were all improved. Importantly, rapamycin also attenuates the severity of established nephritis 176 . In patients with SLE, rapamycin improved clinical outcomes as measured by the reduc tion of overall SLE Disease Activity Index (SLEDAI) and BILAG (British Isles Lupus Assessment Group) scores 6, 109 . More over, a retrospective study showed dimin ished protein uria and improved renal function in six patients with lupus nephritis treated with rapamycin 177 . A prospective openlabel clinical trial of rapamycin in 40 patients with SLE is due for completion in 2015, and should provide additional information about the organ systems that respond to mTOR blockade 178 . Beyond its effects on T cells in SLE, rapamycin blocks fibroblast proliferation, collagen production and dermal fibrosis in the skin 11, 12 and holds promise for the treatment of patients with SSc 15 (TABLE 1) . Interestingly, mTORC2 mediates kidney fibrosis 155 , which could explain the limit ed efficacy of mTORC1 blockade by rapamycin in this setting, and suggests that dual ATPcompetitive mTOR inhibitors might show improved efficacy (TABLE 1) . As noted previously in this Review, rapamycin treat ment enhances the survival of human OA chondrocytes in vitro, whereas genetic inactivation of mTOR prevents OA in mice 55, 159 . These studies suggest that mTOR block ade and stimulation of autophagy in chondrocytes could have therapeutic benefits in OA. Conversely, rapamycin showed limited efficacy in a controlled study of patients with severe psoriasis 179 . The newer agent everolimus pro vided clinical benefit for patients with RA when used in combination with methotrexate, and had an acceptable safety and tolerability profile 8 . Thus, everolimus might offer a new treatment option in patients with RA who have an inadequate response to methotrexate 8 .
PI3K inhibitors
The PI3K-AKT-mTOR pathway is activated in CD4 T cells from mice with lupuslike symptoms induced by graftversushost disease 180 , or as a consequence of the MRL/lpr genetic background 181 , and in those collected from patients with SLE 182 . Accordingly, pharmacolog ical blockade of PI3Kγ with AS605240 blocks Tcell activation, autoantibody production, renal infiltra tion and TNF release by macrophages, and ameliorates glomerulo nephritis, thus extending lifespan in mouse models of lupus 181, 183 . Additionally, the broad PI3K inhib itor LY294002 improves the survival of mesenchymal stem cells (MSCs), which exhibit enhanced senescence in patients with SLE 184 . PI3Kδ is highly expressed in the synovium and cultured FLS of patients with RA 185 , and its expression is selectively induced over other PI3K isoforms by TNF. Moreover, a novel PI3Kδ inhibitor, INK007, blocks TNFinduced AKT activation 185 (TABLE 1) .
N-acetylcysteine
The therapeutic use of NAC in SLE has been based on increasing evidence of oxidative stress being involved in the pathogenesis of this disease 186 , including effects on abnormal Tcell activation 187, 188 , the antigenicity of DNA 189 and self proteins 190 , and production of ANA 191   (TABLE 1) . The rationale for reversing oxidative stress with NAC is supported by several observations. Intracellular GSH levels are decreased in PBLs and T cells from patients with SLE 30, [192] [193] [194] [195] , and GSH depletion and oxi dative stress contribute to Tcell dysfunction in these patients 189, 192, 196 . Additionally, NAC and GSHsparing antioxidants improve the clinical outcome of lupus in mice [197] [198] [199] , and the fact that large dosages (up to 8 g daily) of NAC can be safely administered to humans 200 (and that similar dosages of NAC improve fatigue in healthy individuals 201 ) further supports the use of NAC in this context. NAC also limits the myelotoxicity of immuno suppressive medications 202 , which are also commonly used in patients with SLE.
NAC is inexpensive and widely accessible to patients in healthfood stores, but is currently unavailable as an oral medication by prescription. Therefore, we initi ated a randomized, doubleblind, placebocontrolled phase I-II study to evaluate the safety and tolerability of NAC, as well as its metabolic, immunological and thera peutic effects, in 36 patients with SLE. The results of this study indicate that NAC is safe and reduces disease activ ity and fatigue over 3 months 70 . The therapeutic action of NAC is mediated by the reversal of GSH depletion and blockade of mTORC1 (REF. 70 ), which is a sensor of oxida tive stress [28] [29] [30] 33, 79 . The clinical efficacy of NAC in patients with SLE is hypothesized to occur through a newly iden tified molecular mechanism: disruption of the mitochon drial hyperpolarization (MHP)-oxidative stress-mTOR axis in T cells 186 . DN T cells exhibit the greatest mTORC1 activation 70, 109 and are predisposed to proinflammatory necrotic cell death 70, 109 ; consequently, along with the blockade of their mTORC1 activity, proliferation of these cells is reversed by NAC treatment 70 . Thus, elimination of DN T cells can contribute to the efficacy of NAC.
The use of NAC instead of rapamycin to block mTOR might have additional benefits. Rapamycin induces hyper lipidaemia, at least in renal transplant recipients 203 , and infections are common adverse events in these patients, with pneumonia and sepsis being most frequent 204 . These unwanted consequences of rapamycin are of con cern, because infections and cardiovascular disease are the leading causes of mortality in patients with SLE 205 . Thus, given that oxidative stress contributes to cardio vascular disease 206 , patients might have additional bene fit from treatment with NAC instead of rapamycin, at least those with endstage renal disease 207 . Future studies should focus on whether GSH depletion and activation of mTORC1 predict responsiveness to treatment by NAC and mTOR inhibitors, and whether selective or non selective mTORC1, mTORC2 or dual mTORC1/mTORC2 inhibitors deliver differential clinical benefits (TABLE 1) .
Targets under development
Metformin activates AMPK and, thus, inhibits mTORC1 (REF. 208 ; TABLE 1). Metformin also reduces mTORC1 activity by moderating mitochondrial oxidative stress, which has been implicated in the prevention of nephri tis in lupusprone mice 128 , and inhibits inflamma tory arthritis in the K/B × N model of lupus 209 . Beyond inhibiting mTORC1dependent inflammation, met formin might also reduce metabolic comorbidities such as hyperlipidaemia and atherosclerosis in patients with SLE or RA 210 . Fingolimod, a S1Preceptor antagonist with effects upstream of mTORC1 (REFS 211, 212) , has been introduced for the treatment of multiple sclerosis 213 . Fingolimod sequesters lymphocytes in the secondary lymphoid organs by inducing S1P receptor internalization and degradation 213 , and blocks the expansion of DN T cells and prevents nephritis in MRL/lpr mice 214, 215 . Given their potentially synergistic mechanism of action, fingolimod, metformin, NAC and rapamycin might be combined for the treatment of these autoimmune diseases.
Among the pharmacological interventions currently in preclinical development for the treatment of rheumatic diseases, targeting of calcium/calmodulindependent protein kinase type IV (CaMKIV) seems to be promis ing (TABLE 1) . Overexpression of CaMKIV in T cells from lupusprone mice 216 might act upstream of mTORC1; but given that rapamycin treatment in vivo restores Tcell activationinduced Ca2+ fluxing 6 , CaMKIV might also act downstream of mTORC1. Similarly to mTORC1 blockade, pharmacological inhibition of CaMKIV with KN93 expanded TREG cells 217 , decreased the expres sion of the costimulatory molecules CD86 and CD80 on B cells, decreased ANA production and suppressed nephritis and skin disease in MRL/lpr mice 218 . KN93 also inhibited CaMKII in vitro, and blocked the prolifer ation of FLSs from patients with RA 219 . Another CaMKII inhibitor, rimacalib, which has antiinflammatory effects on macrophages 220 , has entered clinical trials for the treatment of RA (TABLE 1) .
Conclusions
The activation of mTORC1 observed in patients with rheumatic diseases is particularly relevant in light of the fact that these individuals have reduced life expectancy. mTORC1 blockade with rapamycin increases lifespan in mice 160 , and enhanced mTORC1 activation 221 and related autophagy defects are implicated in endothelial inflamma tion, atherosclerosis and vascular ageing 222 . Remarkably, rapamycin also inhibits vascular ageing 222, 223 . These pre clinical studies provided a rationale for new clinical trials aimed at improving cardiovascular outcomes and overall survival in elderly individuals. Such clinical benefit could be highly relevant for patients with SLE or RA, in whom cardiovascular disease is a major cause of increased mor tality 205, [224] [225] [226] . Therefore, mTOR blockade might be highly beneficial for patients with these rheumatic diseases by reducing mortality due to cardiovascular disease, arthritis, nephritis or neurological disease.
Despite these potential advantages, the blockade of mTORC1 with rapamycin or everolimus has unique adverse effects 227 . Mucositis, rash, metabolic derange ments such as hyperglycaemia, hyperlipidaemia and hypophosphataemia 227 , and an increased risk of infec tions 204 are among the most common adverse effects of rapamycin or everolimus in patients who had a renal transplant 203 . The latter are of particularly concern, as infections are a leading cause of increased mortality in patients with SLE 205 and are more common in patients with RA than in the general population 228 . Notably, inhibition of mTORC1 by agents that act at metabolic checkpoints -such as the reversal of GSH depletion and oxidative stress by NAC 70 -can reduce the toxicity of this therapeutic approach, and has the added bene fit of reducing cardiovascular disease 207 . NAC might also benefit patients with RA by moderating the toxicity of methotrexate 229 , which remains a mainstay of treat ment in these patients. Future studies should determine whether oxidative stress, GSH depletion and activation of mTORC1 predict responsiveness to treatment with NAC, metformin and other mTOR inhibitors, alone or in combination, in patients with rheumatic diseases.
